{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:22:54Z","timestamp":1776446574138,"version":"3.51.2"},"reference-count":61,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.bbr.2003.08.016","type":"journal-article","created":{"date-parts":[[2003,10,15]],"date-time":"2003-10-15T19:06:45Z","timestamp":1066244805000},"page":"191-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"151","author":[{"given":"J.","family":"Srinivasan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner J.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2003.08.016_BIB1","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/1531-8257(199911)14:6<911::AID-MDS1001>3.0.CO;2-H","article-title":"Levodopa in the treatment of Parkinson\u2019s disease: a consensus meeting","volume":"14","author":"Agid","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2003.08.016_BIB2","unstructured":"Antelman SN, Caggiula AR. Norepinephrine-dopamine interactions: one step beyond. In: Briley M, Marien M, editors. Noradrenergic mechanisms in Parkinson\u2019s disease. Boca Raton: CRC Press; 1994. p. 127\u201338."},{"key":"10.1016\/j.bbr.2003.08.016_BIB3","unstructured":"Alvord Jr EC, Forno LS. Pathology. In: Koller WC, editor. Handbook of Parkinson\u2019s disease. New York: Marcel Dekker; 1992. p. 258\u20139."},{"key":"10.1016\/j.bbr.2003.08.016_BIB4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/BF01271191","article-title":"Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys","volume":"103","author":"Arai","year":"1996","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.bbr.2003.08.016_BIB5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0006-8993(94)90534-7","article-title":"Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra","volume":"668","author":"Bing","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.bbr.2003.08.016_BIB6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ana.104","article-title":"Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson\u2019s disease","volume":"49","author":"Blandini","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbr.2003.08.016_BIB7","first-page":"798","article-title":"Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hxdroxydopamine lesions of the nigrostriatal pathway","volume":"288","author":"Chopin","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2003.08.016_BIB8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0361-9230(91)90106-T","article-title":"Effects of an alpha 2 antagonist in a 20-year-old Java monkey with MPTP-induced parkinsonian signs","volume":"26","author":"Colpaert","year":"1991","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bbr.2003.08.016_BIB9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF02146939","article-title":"Accumulation of dopamine in the parenchyma after decarboxylase inhibition in the capillaries of brain","volume":"24","author":"Constantinidis","year":"1968","journal-title":"Experientia"},{"key":"10.1016\/j.bbr.2003.08.016_BIB10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0014-2999(82)90367-3","article-title":"Alpha 1- and alpha 2-adrenoceptors in rat cerebral cortex: effects of neonatal treatment with 6-hydroxydopamine","volume":"78","author":"Dausse","year":"1982","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbr.2003.08.016_BIB11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.mp.4000904","article-title":"Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex","volume":"6","author":"Devoto","year":"2001","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbr.2003.08.016_BIB12","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/j.1471-4159.1981.tb00414.x","article-title":"Conversion of 3,4-dihydroxyphenylalanine and deuterated 3,4-dihydroxyphenylalanine to alcoholic metabolites of catecholamines in rat brain","volume":"36","author":"Edwards","year":"1981","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.bbr.2003.08.016_BIB13","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/BF01485901","article-title":"Verteilung von Noradrenalin und Dopamin im Gehirn des Menschen und ihn Verholten bei Erkrankungen des extrapyramidalen systems","volume":"38","author":"Ehringer","year":"1960","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.bbr.2003.08.016_BIB14","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1007\/s100720200077","article-title":"Noradrenergic loss enhances MDMA toxicity and induces ubiquitin-positive striatal whorls","volume":"23","author":"Ferrucci","year":"2002","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.bbr.2003.08.016_BIB15","first-page":"100","article-title":"Effects of noradrenergic lesions on MPTP\/MPP + kinetics and MPTP-induced nigrostriatal dopamine depletions","volume":"283","author":"Fornai","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2003.08.016_BIB16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-2999(95)00313-A","article-title":"Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice","volume":"283","author":"Fornai","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbr.2003.08.016_BIB17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1046\/j.1471-4159.1999.0720777.x","article-title":"Effects of pretreatment with N-(2-chloroethyl)-N-ethyl-2-Bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and strital dopamine losses","volume":"72","author":"Fornai","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbr.2003.08.016_BIB18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0006-8993(96)00891-8","article-title":"Norepinephrine loss selectively enhances chronic nigrostriatal dopamine depletion in mice and rats","volume":"735","author":"Fornai","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.bbr.2003.08.016_BIB19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.1148","article-title":"Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan","volume":"16","author":"Fox","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2003.08.016_BIB20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF00431633","article-title":"Relationship between tardive dyskinesia, L-Dopa-induced hyperkinesia and parkinsonism","volume":"51","author":"Gerlach","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bbr.2003.08.016_BIB21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0149-7634(00)00028-2","article-title":"The role of the locus coeruleus in the development of Parkinson\u2019s disease","volume":"24","author":"Gesi","year":"2000","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bbr.2003.08.016_BIB22","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1046\/j.1460-9568.2003.02692.x","article-title":"A damage to locus coeruleus neurons converts sporadic seizures into self- sustaining limbic status epilepticus","volume":"17","author":"Giorgi","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbr.2003.08.016_BIB23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ana.410060324","article-title":"Chronic agonist-induced hypersensitivity and on-off hyperkinesis","volume":"6","author":"Goetz","year":"1979","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbr.2003.08.016_BIB24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s002109900167","article-title":"Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys","volume":"361","author":"Grondin","year":"2000","journal-title":"Naunyn. Schmiedebergs Arch Pharmacol."},{"key":"10.1016\/j.bbr.2003.08.016_BIB25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1034\/j.1600-0773.2000.pto860501.x","article-title":"Lesioning of locus coeruleus projections by DSP-4 neurotoxin treatment: effect on amphetamine-induced hyperlocomotion and dopamine D2 receptor binding in rats","volume":"86","author":"Harro","year":"2000","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.bbr.2003.08.016_BIB26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0091-3057(80)90254-3","article-title":"A rapid method for the regional dissection of the rat brain","volume":"13","author":"Heffner","year":"1980","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbr.2003.08.016_BIB27","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7","article-title":"The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson\u2019s disease","volume":"14","author":"Henry","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2003.08.016_BIB28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0306-4522(91)90180-V","article-title":"Selective retention of MPP+ within the dopaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study","volume":"40","author":"Herkenham","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2003.08.016_BIB29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000139184","article-title":"3-O-Methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse","volume":"48","author":"Himori","year":"1994","journal-title":"Pharmacology"},{"key":"10.1016\/j.bbr.2003.08.016_BIB30","first-page":"19","article-title":"Biochemical pathophysiology of Parkinson\u2019s disease","volume":"45","author":"Hornykiewicz","year":"1987","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.bbr.2003.08.016_BIB31","first-page":"1105","article-title":"Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson\u2019s disease","volume":"267","author":"Hossain","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2003.08.016_BIB32","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1046\/j.1460-9568.2002.02014.x","article-title":"In vivo regulation of dopamine and noradrenaline release by \u03b12A-adrenoceptors in the mouse prefrontal cortex","volume":"15","author":"Ihalainen","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbr.2003.08.016_BIB33","first-page":"566","article-title":"Neuroleptic-induced tardive dyskinesia","volume":"87","author":"Jenner","year":"1987","journal-title":"Acta Psychiatr. Belg."},{"key":"10.1016\/j.bbr.2003.08.016_BIB34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/0028-3908(87)90072-4","article-title":"Chronic pharmacological manipulation of dopamine receptors in brain","volume":"26","author":"Jenner","year":"1987","journal-title":"Neuropharmacology"},{"issue":"Suppl 2","key":"10.1016\/j.bbr.2003.08.016_BIB35","first-page":"105","article-title":"Newer therapies for Parkinson\u2019s disease","volume":"30","author":"Korczyn","year":"1996","journal-title":"Neurol. Neurochir. Pol."},{"issue":"Suppl 1","key":"10.1016\/j.bbr.2003.08.016_BIB36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000113452","article-title":"Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications","volume":"38","author":"Kuno","year":"1997","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.bbr.2003.08.016_BIB37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0014-2999(93)90489-5","article-title":"Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice","volume":"236","author":"Marien","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbr.2003.08.016_BIB38","unstructured":"Marien M, Lategan A, Colpaert FC. Noradrenergic control of striatal dopamine. In: Briley M, Marien M, editors. Noradrenergic mechanisms in Parkinson\u2019s disease. Boca Raton: CRC Press; 1994. p. 127\u201338."},{"key":"10.1016\/j.bbr.2003.08.016_BIB39","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1006\/exnr.1998.6942","article-title":"Neuroprotective effects of the \u03b12-adrenoceptor antagonists (+)-Efaroxan and (\u00b1)-idazoxan, against quinolinic acid-induced lesions of the rat striatum","volume":"154","author":"Martel","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbr.2003.08.016_BIB40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0022-510X(96)00049-4","article-title":"The metabolism of L-DOPA and l-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients","volume":"139","author":"Maruyama","year":"1996","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbr.2003.08.016_BIB41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0306-4522(91)90345-O","article-title":"Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson\u2019s disease","volume":"41","author":"Mavridis","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2003.08.016_BIB42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0014-2999(85)90201-8","article-title":"Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP","volume":"116","author":"Melamed","year":"1985","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbr.2003.08.016_BIB43","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0091-3057(86)90380-1","article-title":"Increase in beta- and alpha 1-adrenoceptor binding sites in the rat brain and in the alpha 1-adrenoceptor functional sensitivity after the DSP-4-induced noradrenergic denervation","volume":"25","author":"Mogilnicka","year":"1986","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbr.2003.08.016_BIB44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0006-8993(02)02238-2","article-title":"Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson\u2019s disease","volume":"15","author":"Nakazato","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.bbr.2003.08.016_BIB45","unstructured":"Nutt D, Lalies M, Hudson A. The effects of \u03b12-adrenoceptor antagonists on extracellular dopamine concentrations in the rat striatum. In: Briley M, Marien M, editors. Noradrenergic mechanisms in Parkinson\u2019s disease. Boca Raton: CRC Press, 1994; p. 127\u201338."},{"key":"10.1016\/j.bbr.2003.08.016_BIB46","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/0024-3205(76)90094-1","article-title":"Amphetamine-induced release of dopamine from the substantia nigra in vitro","volume":"19","author":"Paden","year":"1976","journal-title":"Life Sci."},{"key":"10.1016\/j.bbr.2003.08.016_BIB47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0014-2999(82)90626-4","article-title":"Behavioural and biochemical changes following chronic administration of L-dopa to rats","volume":"79","author":"Pycock","year":"1982","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbr.2003.08.016_BIB48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0022-510X(77)90009-0","article-title":"Central deopaminergic receptor supersensitivity and its relevance to Parkinson\u2019s disease","volume":"31","author":"Pycock","year":"1977","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbr.2003.08.016_BIB49","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mds.1143","article-title":"Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson\u2019s disease","volume":"16","author":"Rascol","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2003.08.016_BIB50","first-page":"277","article-title":"Regional effects of l-dihydroxyphenylalanine (L-DOPA) on norepinephrine metabolism in rat brain","volume":"180","author":"Romero","year":"1971","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2003.08.016_BIB51","first-page":"155","article-title":"Basal ganglia dopamine and glutamate in motor activation and plasticity","volume":"6","author":"Schmidt","year":"1998","journal-title":"Neurol Psych Brain Res."},{"key":"10.1016\/j.bbr.2003.08.016_BIB52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF01345235","article-title":"Dopamine-glutamate interactions in the basal ganglia","volume":"14","author":"Schmidt","year":"1998","journal-title":"Amino Acids"},{"key":"10.1016\/j.bbr.2003.08.016_BIB53","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0091-3057(89)90007-5","article-title":"Anticataleptic effects of the N-methyl-d-aspartate antagonist MK-801 in rats","volume":"32","author":"Schmidt","year":"1989","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.bbr.2003.08.016_BIB54","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0306-4522(97)00570-8","article-title":"The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter","volume":"84","author":"Speciale","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2003.08.016_BIB55","unstructured":"Srinivasan J, Schmidt WJ. Potentiation of Parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur J Neurosci, In press."},{"key":"10.1016\/j.bbr.2003.08.016_BIB56","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0306-4522(85)90269-6","article-title":"Alpha 1- and beta-adrenergic receptors are co-regulated during both noradrenergic denervation and hyperinnervation","volume":"14","author":"Sutin","year":"1985","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2003.08.016_BIB57","unstructured":"Tassin JP, Trovero F, Blanc G, Herve D, Glowinski J. Interactions between noradrenaline and dopamine neurotransmission in the rat prefrontal cortex and their consequences on dopaminergic subcortical function. In: Briley M, Marien M, editors. Noradrenergic mechanisms in Parkinson\u2019s disease. Boca Raton, CRC Press; 1994. p. 127\u201338."},{"key":"10.1016\/j.bbr.2003.08.016_BIB58","first-page":"363","article-title":"Experimental models of Parkinson\u2019s disease: insights from many models","volume":"49","author":"Tolwani","year":"1999","journal-title":"Lab. Anim. Sci."},{"key":"10.1016\/j.bbr.2003.08.016_BIB59","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1212\/WNL.49.3.717","article-title":"In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson\u2019s disease patients with and without dyskinesias","volume":"49","author":"Turjanski","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.bbr.2003.08.016_BIB60","first-page":"75","article-title":"Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease","volume":"14","author":"Verhagen","year":"1997","journal-title":"Amino Acids"},{"key":"10.1016\/j.bbr.2003.08.016_BIB61","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archneur.60.3.337","article-title":"Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases","volume":"60","author":"Zarow","year":"2003","journal-title":"Arch Neurol."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432803003024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432803003024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T03:48:10Z","timestamp":1711597690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432803003024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":61,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0166432803003024"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2003.08.016","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2003.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}